Acute lymphocytic leukemia
Amgen Acquires Oxford Spinout Dark Blue Therapeutics for Up to $840 Million, Gaining Preclinical Cancer Drug
Amgen; Dark Blue Therapeutics; acquisition; Oxford spinout; DBT 3757; AML; ALL; protein degrader
Xspray’s Dasynoc Faces FDA Approval Delay Due to Contract Manufacturing Issues
Dasynoc; Xspray Pharma; FDA; Complete Response Letter; manufacturing issues; good manufacturing practice; contract manufacturer; chronic myeloid leukemia; acute lymphoblastic leukemia; drug approval process
Orca’s cell therapy trounces traditional care in blood cancer phase 3, swimming into space’s ‘holy grail’
allogeneic hematopoietic stem cell transplant with purging, Leukemia, Myelocytic, Acute, Acute lymphocytic leukemia
Amgen’s Blincyto Wins FDA Approval for Expanded Leukemia Use
Blincyto, Amgen, FDA Approval, Leukemia Treatment, Minimal Residual Disease (MRD), Acute Lymphoblastic Leukemia (ALL), Bispecific Antibody